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We examine some aspects of the South African health system that have
contributed to the current multi- and extensively drug-resistant tuberculosis
(M(X)DR-TB) epidemic and identify opportunities for change and improve-
ment. Implementation of several recent major scientific advances have the
potential to accelerate the control of M(X)DR-TB, but health systems strength-
ening will be essential.
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Decades of sub-standard, poorly implemented tuberculosis (TB) control pro-
gramme guidelines and interrupted TB treatment, combined with neglect in drug
development, has seen the emergence of both multi- and extensively-drug resistant
TB [M(X)DR-TB] [1] -- a public health crisis of particular concern in South Africa
where both TB and HIV epidemics have converged. Therapeutic options for drug-
resistant TB are limited by efficacy, acceptability, availability, tolerability and finan-
cial constraints. Since 2006, the number of M(X)DR-TB cases in South Africa has
increased temporally [2] and in 2013 the WHO identified South Africa as having the
second-highest number of MDR-TB cases worldwide [3]. Since the prevalence of
drug-resistant TB is considered a measure of the effectiveness of existing TB control
programmes [4], these statistics emphasise grave inadequacies in current treatment
and management strategies for TB in South Africa and highlight an ailing health
system. Here, we examine aspects of the South African public health system which
have contributed to the current situation and evaluate the role of scientific advances
in the control of drug-resistant TB.
The treatment of M(X)DR-TB is protracted, toxic, resource-intensive [5] and
plagued by poor patient adherence [6]. South African data for the period 2000 --
2004 show that standardised treatment for MDR-TB resulted in an overall treat-
ment success rate of only 46% [7]. The mortality rate in HIV-infected patients
was 35.2%, more than double than in HIV-negative patients [7]. Treatment success
rates are considerably lower in XDR-TB, an ominous threat to gains made in HIV-
TB programmes. A 24-month study of XDR-TB in South Africa in which 73% of
the cohort was HIV co-infected, but only 61% received combined anti-retroviral
therapy (cART), reported a treatment success rate of just 22% [8]. Since then there
has been compelling scientific evidence demonstrating the role of concurrent
second-line anti-TB chemotherapy and cART administration in improving sputum
conversion rates and reducing mortality in M(X)DR-TB-HIV co-infected
patients [8-10]. Encouragingly, the National Tuberculosis Programme responded
and the South African ART guidelines were amended in 2010 to incorporate the
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recommendation that TB-HIV co-infected patients be initi-
ated on cART irrespective of the CD4 cell count. Three years
on, data from the third quarter of 2013, at one of the largest
TB drug-resistant treatment facilities in South Africa, show
that 19% of MDR-TB-HIV co-infected patients were not ini-
tiated on cART.
There is some evidence that operational challenges in
implementing the current guidelines and the sub-optimal
use of existing drugs contribute to low treatment success
rates [11]. Such operational challenges occur at various levels
of the health system. A recent study describes the treatment
journey of a typical patient, and highlights numerous flaws
within a health system that ultimately fails its dependants [12].
A 6-week time lag for notification of culture results; a month’s
delay in hospital admission due to limited inpatient capacity;
incomplete treatment regimens as a result of drug stock-outs
and delayed cART initiation (attributable to poor integration
of TB and HIV services) have since informally been accepted
as ‘standard of care’. Alarmingly, recent data, from another
province in South Africa, show that only 63% of newly
diagnosed MDR-TB patients initiated treatment in
2011 [13]. Further, a random chart review of 186 patients
referred to a centralised MDR-TB facility in KwaZulu-Natal
in 2010 show that only 25% were initiated on treatment
within 8 weeks, leaving 75% of patients experiencing a
mean delay of 12.36 weeks (in addition to the 6 -- 8 weeks
required for culture and susceptibility testing) [14]. Such
issues, in conjunction with patient-related socioeconomic
problems make the Millennium Development Goal of
eradicating TB by 2050 elusive in this resource-poor setting.
Novel anti-TB agents such as bedaquiline and delamanid
and re-purposed drugs such as linezolid, significantly short-
ened treatment programmes such as the ‘Bangladesh Regi-
men’ [11] and innovative point-of-care diagnostics such as
Xpert MTB/RIF personify the scientific advances considered
essential in regaining control of drug-resistant TB but the
question remains whether they can have the desired impact
on their own.
The advent of Xpert MTB/RIF has since substantially
reduced the time to MDR-TB treatment initiation by
approximately two-thirds at some sites in South Africa (Dr
Iqbal Master, personal communication, October 2013);
however, its ability to provide a diagnosis within a few
hours suggests that this delay could, in theory, be further
reduced. Xpert MTB/RIF has also paradoxically further
intensified the burden, increasing MDR-TB case detection
resulting in an escalation in the number MDR-TB cases ini-
tiated on treatment (Figure 1) and an unwavering patient
admission waiting list (Figure 2). Figure 2 illustrates the
number of patients with M(X)DR-TB awaiting admission
at a TB specialist hospital with a maximum capacity of
192 beds, over a 7-year period. Although fluctuating, the
numbers remain unacceptably high and reveal a lack of
intervention to ensure a sustained decline in waiting time,
despite this facility initiating treatment in 65% of patients
in outpatient care. The limited inpatient capacity has other
important public health implications. Pietersen et al. found
that 42% of patients with XDR-TB who were discharged
had failed treatment [15]. Further, these patients had a
median survival time of 19.84 months from the time of dis-
charge. These data reveal a critical gap in current TB con-
trol programmes where potential disease transmission
requires urgent interruption.
Unlike scientific advances, TB control programmes appear
to have stagnated. These factors demonstrate a health system
unable to exploit the potential of available resources. Cumula-
tively, they are an ominous threat to drug-resistant TB con-




























Figure 1. Data regarding the Number of MDR-TB cases initiated on treatment at a TB specialist hospital in South Africa
between 1995 and 2013.
Estimated figure is based on data available for the first three quarters of 2013.
MDR-TB: Multi-drug-resistant tuberculosis.
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fuelling transmission in vulnerable communities, urgently
requiring strategic intervention.
Expert opinion
Major developments in drug availability, shortened, better-
tolerated treatment regimens and innovative diagnostic tools
have the potential to vastly enhance current programmes
and accelerate the control of M(X)DR-TB. Although these
advances highlight the way forward, they too will inevitably
fail in a fragile health system. The burden of the M(X)DR-
TB has prompted a culture that strives towards quantity
as opposed to quality of healthcare administered, often
neglecting to implement even the most basic principles of
care without capitalising on available tools. It is imperative
that we do not underestimate the role and value of health
systems’ strengthening. We need to identify weaknesses and
develop strategies that target such limitations. Stakeholder
commitment to TB control, improved provider performance
and enhanced morale in healthcare workers, combined with
the necessary support and infrastructure, will be essential in
containing the scourge of this disease. Unless these interven-
tions complement each other, an unfortunate outcome is
inevitable.
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Figure 2. Data regarding the number of patients awaiting treatment initiation and admission at a TB specialist hospital in
South Africa between 2006 and 2013.
TB: Tuberculosis.
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